TY - JOUR AU - Citri, A. AU - Yarden, Y. PY - 2006 DA - 2006// TI - EGF-ERBB signalling: towards the systems level JO - Nat Rev Mol Cell Biol VL - 7 UR - https://doi.org/10.1038/nrm1962 DO - 10.1038/nrm1962 ID - Citri2006 ER - TY - JOUR AU - Yarden, Y. AU - Sliwkowski, M. X. PY - 2001 DA - 2001// TI - Untangling the ErbB signalling network JO - Nat Rev Mol Cell Biol VL - 2 UR - https://doi.org/10.1038/35052073 DO - 10.1038/35052073 ID - Yarden2001 ER - TY - JOUR AU - Mosesson, Y. AU - Mills, G. B. AU - Yarden, Y. PY - 2008 DA - 2008// TI - Derailed endocytosis: an emerging feature of cancer JO - Nat Rev Cancer VL - 8 UR - https://doi.org/10.1038/nrc2521 DO - 10.1038/nrc2521 ID - Mosesson2008 ER - TY - JOUR AU - Clague, M. J. AU - Liu, H. AU - Urbe, S. PY - 2012 DA - 2012// TI - Governance of endocytic trafficking and signaling by reversible ubiquitylation JO - Dev Cell VL - 23 UR - https://doi.org/10.1016/j.devcel.2012.08.011 DO - 10.1016/j.devcel.2012.08.011 ID - Clague2012 ER - TY - JOUR AU - Sigismund, S. PY - 2008 DA - 2008// TI - Clathrin-mediated internalization is essential for sustained EGFR signaling but dispensable for degradation JO - Dev Cell VL - 15 UR - https://doi.org/10.1016/j.devcel.2008.06.012 DO - 10.1016/j.devcel.2008.06.012 ID - Sigismund2008 ER - TY - JOUR AU - Sigismund, S. PY - 2013 DA - 2013// TI - Threshold-controlled ubiquitination of the EGFR directs receptor fate JO - EMBO J VL - 32 UR - https://doi.org/10.1038/emboj.2013.149 DO - 10.1038/emboj.2013.149 ID - Sigismund2013 ER - TY - JOUR AU - Capuani, F. PY - 2015 DA - 2015// TI - Quantitative analysis reveals how EGFR activation and downregulation are coupled in normal but not in cancer cells JO - Nat Commun VL - 6 UR - https://doi.org/10.1038/ncomms8999 DO - 10.1038/ncomms8999 ID - Capuani2015 ER - TY - JOUR AU - Kandoth, C. PY - 2013 DA - 2013// TI - Mutational landscape and significance across 12 major cancer types JO - Nature VL - 502 UR - https://doi.org/10.1038/nature12634 DO - 10.1038/nature12634 ID - Kandoth2013 ER - TY - JOUR PY - 2014 DA - 2014// TI - Comprehensive molecular profiling of lung adenocarcinoma JO - Nature VL - 511 UR - https://doi.org/10.1038/nature13385 DO - 10.1038/nature13385 ID - ref9 ER - TY - JOUR AU - Mitsudomi, T. AU - Yatabe, Y. PY - 2010 DA - 2010// TI - Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer JO - FEBS J VL - 277 UR - https://doi.org/10.1111/j.1742-4658.2009.07448.x DO - 10.1111/j.1742-4658.2009.07448.x ID - Mitsudomi2010 ER - TY - JOUR AU - Pines, G. AU - Kostler, W. J. AU - Yarden, Y. PY - 2010 DA - 2010// TI - Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy JO - FEBS Lett VL - 584 UR - https://doi.org/10.1016/j.febslet.2010.04.019 DO - 10.1016/j.febslet.2010.04.019 ID - Pines2010 ER - TY - JOUR AU - Sharma, S. V. PY - 2007 DA - 2007// TI - Epidermal growth factor receptor mutations in lung cancer JO - Nat Rev Cancer VL - 7 UR - https://doi.org/10.1038/nrc2088 DO - 10.1038/nrc2088 ID - Sharma2007 ER - TY - JOUR AU - Shigematsu, H. AU - Gazdar, A. F. PY - 2006 DA - 2006// TI - Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers JO - Int J Cancer VL - 118 UR - https://doi.org/10.1002/ijc.21496 DO - 10.1002/ijc.21496 ID - Shigematsu2006 ER - TY - JOUR AU - Sorkin, A. AU - von Zastrow, M. PY - 2009 DA - 2009// TI - Endocytosis and signalling: intertwining molecular networks JO - Nat Rev Mol Cell Biol VL - 10 UR - https://doi.org/10.1038/nrm2748 DO - 10.1038/nrm2748 ID - Sorkin2009 ER - TY - JOUR AU - Sorkin, A. AU - Goh, L. K. PY - 2009 DA - 2009// TI - Endocytosis and intracellular trafficking of ErbBs JO - Exp Cell Res VL - 315 UR - https://doi.org/10.1016/j.yexcr.2008.07.029 DO - 10.1016/j.yexcr.2008.07.029 ID - Sorkin2009 ER - TY - JOUR AU - Goh, L. K. AU - Sorkin, A. PY - 2013 DA - 2013// TI - Endocytosis of receptor tyrosine kinases JO - Cold Spring Harb Perspect Biol VL - 5 UR - https://doi.org/10.1101/cshperspect.a017459 DO - 10.1101/cshperspect.a017459 ID - Goh2013 ER - TY - JOUR AU - Chung, B. M. PY - 2014 DA - 2014// TI - Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants JO - World J Clin Oncol VL - 5 UR - https://doi.org/10.5306/wjco.v5.i5.806 DO - 10.5306/wjco.v5.i5.806 ID - Chung2014 ER - TY - JOUR AU - Hampton, K. K. AU - Craven, R. J. PY - 2014 DA - 2014// TI - Pathways driving the endocytosis of mutant and wild-type EGFR in cancer JO - Oncoscience VL - 1 UR - https://doi.org/10.18632/oncoscience.67 DO - 10.18632/oncoscience.67 ID - Hampton2014 ER - TY - JOUR AU - Furukawa, M. PY - 2007 DA - 2007// TI - Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis JO - DNA Cell Biol VL - 26 UR - https://doi.org/10.1089/dna.2006.0573 DO - 10.1089/dna.2006.0573 ID - Furukawa2007 ER - TY - JOUR AU - Shtiegman, K. PY - 2007 DA - 2007// TI - Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling JO - Oncogene VL - 26 UR - https://doi.org/10.1038/sj.onc.1210503 DO - 10.1038/sj.onc.1210503 ID - Shtiegman2007 ER - TY - JOUR AU - Padron, D. PY - 2007 DA - 2007// TI - Epidermal growth factor receptors with tyrosine kinase domain mutations exhibit reduced Cbl association, poor ubiquitylation, and down-regulation but are efficiently internalized JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-0484 DO - 10.1158/0008-5472.CAN-07-0484 ID - Padron2007 ER - TY - JOUR AU - Hosaka, T. PY - 2007 DA - 2007// TI - Mutant epidermal growth factor receptor undergoes less protein degradation due to diminished binding to c-Cbl JO - Anticancer Res VL - 27 ID - Hosaka2007 ER - TY - JOUR AU - Yang, S. PY - 2006 DA - 2006// TI - Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-06-1042 DO - 10.1158/0008-5472.CAN-06-1042 ID - Yang2006 ER - TY - JOUR AU - Chen, Y. R. PY - 2006 DA - 2006// TI - Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants JO - Oncogene VL - 25 UR - https://doi.org/10.1038/sj.onc.1209159 DO - 10.1038/sj.onc.1209159 ID - Chen2006 ER - TY - JOUR AU - Wang, M. PY - 2017 DA - 2017// TI - The USP7 inhibitor P5091 induces cell death in ovarian cancers with different P53 status JO - Cell Physiol Biochem VL - 43 UR - https://doi.org/10.1159/000484062 DO - 10.1159/000484062 ID - Wang2017 ER - TY - JOUR AU - Zhang, Y. PY - 2016 DA - 2016// TI - Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells JO - Cancer Lett VL - 382 UR - https://doi.org/10.1016/j.canlet.2016.08.026 DO - 10.1016/j.canlet.2016.08.026 ID - Zhang2016 ER - TY - JOUR AU - Caldieri, G. PY - 2017 DA - 2017// TI - Reticulon 3-dependent ER-PM contact sites control EGFR nonclathrin endocytosis JO - Science VL - 356 UR - https://doi.org/10.1126/science.aah6152 DO - 10.1126/science.aah6152 ID - Caldieri2017 ER - TY - JOUR AU - Sawai, A. PY - 2008 DA - 2008// TI - Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-07-1570 DO - 10.1158/0008-5472.CAN-07-1570 ID - Sawai2008 ER - TY - JOUR PY - 2015 DA - 2015// TI - Causes of death, Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013 JO - Lancet VL - 385 UR - https://doi.org/10.1016/S0140-6736(14)61682-2 DO - 10.1016/S0140-6736(14)61682-2 ID - ref29 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2016 DA - 2016// TI - Cancer statistics, 2016 JO - CA Cancer J Clin VL - 66 UR - https://doi.org/10.3322/caac.21332 DO - 10.3322/caac.21332 ID - Siegel2016 ER - TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2017 DA - 2017// TI - Cancer statistics, 2017 JO - CA Cancer J Clin VL - 67 UR - https://doi.org/10.3322/caac.21387 DO - 10.3322/caac.21387 ID - Siegel2017 ER - TY - JOUR AU - Bruckl, W. AU - Tufman, A. AU - Huber, R. M. PY - 2017 DA - 2017// TI - Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs JO - Expert Rev Anticancer Ther VL - 17 UR - https://doi.org/10.1080/14737140.2017.1266265 DO - 10.1080/14737140.2017.1266265 ID - Bruckl2017 ER - TY - JOUR AU - Tan, D. S. PY - 2016 DA - 2016// TI - The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung Cancer: status in 2016 JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.008 DO - 10.1016/j.jtho.2016.05.008 ID - Tan2016 ER - TY - JOUR AU - Sequist, L. V. PY - 2011 DA - 2011// TI - Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors JO - Sci Transl Med VL - 3 UR - https://doi.org/10.1126/scitranslmed.3002003 DO - 10.1126/scitranslmed.3002003 ID - Sequist2011 ER - TY - JOUR AU - Yu, H. A. PY - 2013 DA - 2013// TI - Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-2246 DO - 10.1158/1078-0432.CCR-12-2246 ID - Yu2013 ER - TY - JOUR AU - Roskoski, R. PY - 2014 DA - 2014// TI - ErbB/HER protein-tyrosine kinases: structures and small molecule inhibitors JO - Pharmacol Res VL - 87 UR - https://doi.org/10.1016/j.phrs.2014.06.001 DO - 10.1016/j.phrs.2014.06.001 ID - Roskoski2014 ER - TY - JOUR AU - Sanchez-Martin, M. AU - Pandiella, A. PY - 2012 DA - 2012// TI - Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications JO - Int J Cancer VL - 131 UR - https://doi.org/10.1002/ijc.26358 DO - 10.1002/ijc.26358 ID - Sanchez-Martin2012 ER -